No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Nanox Imaging Announcement: Secures over $100M in Crossover Equity Investments

Editor: What To Know

  • The Company aims to revolutionize early-detection healthcare by deploying a global medical imaging infrastructure at an affordable price-per-scan service model to maximize the availability and accessibility of medical imaging to all socio-economic communities.
  • As a strategic investor, The Yozma Group Asia is eager to make a global success case of Asian and Israeli collaboration by merging Nanox innovative technology and Korea's outstanding manufacturing knowhow.
  • “I'm honored to be a part of the Nanox project not only because its technology is groundbreaking and contributing to mankind, but also because it's the best example of multinational collaboration.

Nanox Imaging (Nanox) today reports they have secured over $100M in crossover equity investments. The news was announced today. Israeli-based A-Labs Advisory and Finance Ltd. was the lead advisor to the financing round.

The funds raised are planned to primarily support the rollout of the Nanox.ARC deployments worldwide.

The financing round was initiated in November 2019 and was delayed in closing due to the COVID-19 pandemic. Since November 2019, Nanox has signed agreements for the deployment of thousands of units of the Nanox System, its innovative medical imaging system, and diagnostics services in eleven global regions. The Company aims to revolutionize early-detection healthcare by deploying a global medical imaging infrastructure at an affordable price-per-scan service model to maximize the availability and accessibility of medical imaging to all socio-economic communities.

“It is easy to say that we are aiming to change the world,” says Ran Poliakine, Founder and Chief Executive Officer of Nanox. “The main challenge with such statements is always the execution. We have a bold vision to increase the early detection of medical conditions that are discoverable by X-ray. We are actively working to deploy a global medical imaging service infrastructure that may turn this dream into reality. We cannot do it without partners and investors who share our vision and support our plan. I thank our investors at SK Telecom, Foxconn, Industrial Alliance and Yozma Korea for their faith and trust in the Nanox team and vision.”

“The innovative approach of preventive healthcare and the MEMs X-ray source have driven us, The Yozma Group Asia, to invest in Nanox. Potentially reduced radiation exposure and lowered cost can set a new standard of regular health checkups,” says Wonjae Lee, Head of Asia Pacific and Managing Partner of Yozma Group. “I’m honored to be a part of the Nanox project not only because its technology is groundbreaking and contributing to mankind, but also because it’s the best example of multinational collaboration. As a strategic investor, The Yozma Group Asia is eager to make a global success case of Asian and Israeli collaboration by merging Nanox innovative technology and Korea’s outstanding manufacturing knowhow.”

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy